Lymphoplasmacytic variant of multiple myeloma

Diagnostic challenges in plasma cell myeloma with lymphoplasmacytic lymphoma‐feature

“…Specific IHC analysis of PCM (cyclin D1 and CD56) and LPL (PAX5 and LCA) markers and flow cytometry provided valuable diagnostic information necessary to make an accurate diagnosis (Figure 1C). 3,4 This case emphasizes the significance of comprehensive multiple tests to make an accurate diagnosis in a rare subset of PCM.…”

“…clinicians make an accurate diagnosis. 3,4 In regard to clinical relevance, previous studies indicated that PCM exhibiting cyclin D1 expression represents a distinct disease subset characterized by unique biological features, such as harboring t(11;14), higher levels of B-cell lymphoma 2 (BCL-2), and frequent CD20 expression. 1 However, the effect of the above factors on prognosis remains undetermined.…”

“…1 However, the effect of the above factors on prognosis remains undetermined. 1,3,4 A meta-analysis suggests that the expression of cyclin D1 may be linked to favorable clinical outcomes in PCM patients treated with bortezomib. 5 In summary, we encountered a diagnostic dilemma between PCM and LPL based on their morphologies.…”

“…Importantly, the LPL cells were found to be positive for B‐cell markers, including PAX5, and negative for cyclin D1 and lymphoid enhancer‐binding factor 1 (LEF1) in an IHC study 2 . Therefore, an IHC assessment for cyclin D1 expression and chromosomal translocation t(11;14) detected by fluorescent in situ hybridization (FISH) can help clinicians make an accurate diagnosis 3,4 …”

“…In regard to clinical relevance, previous studies indicated that PCM exhibiting cyclin D1 expression represents a distinct disease subset characterized by unique biological features, such as harboring t(11;14), higher levels of B‐cell lymphoma 2 (BCL‐2), and frequent CD20 expression 1 . However, the effect of the above factors on prognosis remains undetermined 1,3,4 . A meta‐analysis suggests that the expression of cyclin D1 may be linked to favorable clinical outcomes in PCM patients treated with bortezomib 5 …”